How many FDA approved Universal CAR-T are there?

Introduction to CAR‑T Cell Therapy

Chimeric antigen receptor T (CAR‑T) cell therapy represents an innovative immunotherapy in which a patient’s T cells are genetically engineered to express synthetic receptors—known as CARs—that can specifically recognize tumor‐associated antigens. Once these modified T cells are reinfused into the patient, they bind to the target antigens on cancer cells, become activated, proliferate, release cytokines, and induce cytotoxicity to eliminate tumor cells. The CAR structure typically includes an extracellular antigen recognition domain (usually a single‐chain variable fragment or scFv), a hinge or spacer region, a transmembrane domain, and intracellular signal transduction domains (including CD3ζ and costimulatory domains such as CD28 or 4‑1BB). This design allows CAR‑T cells to bypass the traditional human leukocyte antigen (HLA) restrictions and provides them the capacity to recognize cell surface antigens directly, thereby facilitating a robust antitumor response.

Overview of CAR‑T in Cancer Treatment 
CAR‑T cell therapy has transformed the treatment landscape for hematological malignancies such as B‐cell acute lymphoblastic leukemia (B‑ALL), diffuse large B‑cell lymphoma (DLBCL) and multiple myeloma, among others. With several autologous CAR‑T cell therapies receiving FDA approval over the past few years (e.g., tisagenlecleucel [Kymriah®], axicabtagene ciloleucel [Yescarta®], and others), remarkable clinical responses have been observed in patient populations that had exhausted conventional therapeutic options. Despite these successes in blood cancers, CAR‑T therapy for solid tumors has shown limited efficacy due to challenges such as tumor heterogeneity, immunosuppressive microenvironments, and inadequate T‑cell infiltration. In this context, considerable research efforts are underway to further optimize CAR‑T constructs, administration protocols, and combination strategies to expand their benefits beyond hematological malignancies.

Universal CAR‑T Therapies

Definition and Advantages over Traditional CAR‑T 
Universal CAR‑T (UCAR‑T) therapies refer to an emerging class of engineered T‑cell products that are designed to be “off‑the‑shelf,” meaning that they are developed from healthy donor cells or from allogeneic sources rather than using a patient’s own cells. Unlike autologous CAR‑T products, which are individually manufactured for each patient and are subject to variability in cell quality and manufacturing time, universal CAR‑T cells offer several advantages: 
- Reduced Manufacturing Time and Cost: By creating an allogeneic product, the lengthy and expensive process of individual cell harvesting and expansion is bypassed, potentially lowering production costs and expediting treatment. 
- Consistent Product Quality: Universal CAR‑T cells can be produced and banked in large quantities from healthy donor sources, ensuring a more standardized and quality‑controlled product. 
- Immediate Availability: Since these cells are pre‐manufactured, patients can have faster access to the therapy, which is critical for aggressive tumors or those that progress rapidly.

Despite these favorable features, universal CAR‑T cells must be carefully engineered to circumvent issues commonly associated with allogeneic transplants, such as host-versus-graft reactions and graft-versus-host disease (GvHD). To address these immune‐related challenges, advanced gene editing strategies (for example, CRISPR/Cas9, TALEN, or ZFN technologies) have been employed to knock out endogenous T‑cell receptors (TCRs) and human leukocyte antigen (HLA) molecules, reducing the immunogenicity of the cell product and minimizing adverse immune reactions.

Development and Innovation in Universal CAR‑T 
The development of universal CAR‑T therapy has been characterized by remarkable innovation in cell engineering. Researchers have focused on eliminating endogenous T‑cell components that can trigger unwanted immune responses. For instance, by knocking out the TCR and HLA class I/II molecules, scientists have created T cells that are less likely to be recognized as foreign by the host immune system, and that have the potential for reduced GvHD. Furthermore, integration of safety switches, such as inducible caspase‑9, provides an additional layer of control which can be activated in case of off‑target toxicity or severe cytokine release syndrome (CRS).

Several recent studies have illustrated the ongoing progress in this area. For example, one study successfully generated triple-deficiency universal CAR‑T cells (TCR/HLA‑I/HLA‑II deficient) and further engineered them with HLA‑E expression to circumvent natural killer (NK) cell–mediated clearance. Research is also examining various approaches to enhance CAR‑T cell persistence and antitumor efficacy by refining their gene expression profiles and functional phenotypes. Despite these technological advancements and promising early-phase clinical data, UCAR‑T therapies remain investigational and have not yet reached the stage of regulatory approval by the FDA.

FDA Approval Process for CAR‑T

Regulatory Pathways and Criteria 
The pathway for FDA approval of CAR‑T cell therapies involves extensive preclinical evaluation, followed by rigorous phased clinical trials. Regulatory agencies evaluate factors such as safety, manufacturing consistency, efficacy, and overall benefit-risk balance. For autologous CAR‑T therapies, the criteria include demonstrating robust clinical efficacy (e.g., high complete remission rates in hard-to-treat cancers) and manageable toxicity profiles. Likewise, any candidate for universal CAR‑T therapy must satisfy these stringent requirements.

Key considerations include: 
- Preclinical Validation: Demonstrating reproducible antitumor activity in animal models, along with detailed toxicity assessments specifically addressing on-target off-tumor effects and immune-related adverse events. 
- Manufacturing Consistency: Ensuring the cell product can be reliably produced with consistent quality from batch to batch is critical, especially for universal CAR‑T products that employ complex gene editing strategies. 
- Clinical Efficacy: Early-phase clinical trials must show sufficient efficacy in initial patient cohorts while monitoring for issues such as relapse, immunogenicity, and long-term cell persistence. 
- Safety Profile: Particular emphasis is placed on safety given the known adverse events associated with CAR‑T therapy, such as CRS and neurotoxicity, and for universal CAR‑T, the additional risk of GvHD from residual allogeneic immune responses.

Challenges in Approval Process 
Universal CAR‑T therapies face unique challenges on the regulatory front. The main hurdles include: 
- Immune Compatibility: The need to mitigate risks of GvHD and host-versus-graft disease (HvGD) means that gene editing must be extremely efficient and verifiable. Any residual expression of T‑cell receptors or HLA molecules could provoke serious immunological reactions. 
- Manufacturing Complexity: Allogeneic CAR‑T products involve more complex manufacturing processes, including gene editing and extensive cell expansion protocols, which can lead to higher variability. Ensuring product homogeneity is critical to satisfying regulatory authorities. 
- Long-term Safety Data: Universal CAR‑T therapies have not yet accrued long-term clinical data comparable to their autologous counterparts. The FDA requires evidence of durable responses and manageable long-term toxicity before granting approval. 
- Cost and Accessibility Considerations: While universal CAR‑T holds promise for reducing costs, the initial development expenses, potential for unforeseen adverse effects, and the need for sophisticated safety switches all contribute to uncertainty in the approval process.

Current FDA Approved Universal CAR‑T Therapies

List of Approved Therapies 
Despite significant innovation and promising preclinical and early-phase clinical studies, as of now there are no FDA approved universal CAR‑T therapies. All of the currently approved CAR‑T therapies by the FDA—such as tisagenlecleucel (Kymriah®), axicabtagene ciloleucel (Yescarta®), lisocabtagene maraleucel (Breyanzi®), and idecabtagene vicleucel (Abecma®)—are autologous in nature. These products are manufactured individually from each patient’s own T cells and do not fall under the umbrella of universal or off‑the‑shelf CAR‑T therapies.

This fact is underscored in several reviews and studies where the emphasis on universal CAR‑T is on its potential and ongoing clinical investigation, rather than on an already approved product. In essence, while universal CAR‑T therapy holds the promise of circumventing the multiple logistical and biological limitations of autologous products, it has not yet successfully navigated the full FDA approval process because accumulated data regarding long-term safety, efficacy, and immune compatibility are still pending.

Clinical Indications and Efficacy 
Since universal CAR‑T therapies remain investigational, there is no officially approved clinical indication for their use. Instead, most of the clinical data have been accrued through early-phase trials targeting hematological malignancies and, to a lesser extent, solid tumors. Clinical investigations are primarily focused on: 
- Evaluating Safety: Studies aim to ensure that gene-edited universal CAR‑T cells can avoid adverse immunological reactions such as GvHD. 
- Assessing Efficacy: Early data indicate potential for potent antitumor responses, but these responses must be confirmed in larger, later-phase studies. 
- Comparative Analysis: Researchers are comparing these products with conventional autologous CAR‑T cells, assessing not only their antitumor efficacy but also parameters like T‑cell persistence, cytokine profiles, and relapse rates.

The absence of FDA approval is largely because these therapies have not yet shown the necessary confirmatory evidence across broader patient populations to meet the strict regulatory criteria established by the FDA for commercialization.

Future Directions and Challenges

Ongoing Research and Trials 
The field of universal CAR‑T therapy is highly dynamic with numerous ongoing preclinical studies and early-phase clinical trials. Research teams worldwide are working diligently on: 
- Improved Gene Editing: Advanced platforms such as CRISPR/Cas9 are being employed to eliminate not only endogenous T‑cell receptors but also HLA molecules, thereby reducing the likelihood of immune rejection. 
- Safety Switch Implementation: Novel genetic safety switches—like inducible caspase‑9 systems—are under investigation to allow rapid deactivation of CAR‑T cells in case of severe adverse events. 
- Multi‑antigen Targeting Strategies: To overcome tumor heterogeneity and antigen escape, dual or tandem CAR constructs are being developed. These strategies are being evaluated to determine if universal CAR‑T cells can maintain durable responses while reducing the risk of relapse. 
- Combining with Other Therapies: Combinatory approaches that include immune checkpoint inhibitors or other conventional therapies are also on the research agenda, seeking to augment the efficacy of universal CAR‑T therapies.

Clinical trial information has already indicated promising early outcomes albeit with a relatively short follow‑up duration. Multiple trials have been registered to evaluate universal CAR‑T in diverse malignancies, and robust collaborations among academic centers, biopharmaceutical companies, and clinical institutions are accelerating the advancement of this technology.

Potential Challenges and Solutions 
Alongside the inherent challenges in manufacturing and immunological compatibility, several issues must be resolved before universal CAR‑T therapies can achieve FDA approval: 
- Ensuring Long-term Safety: Although initial results show manageable toxicity profiles during early-phase trials, long-term data are necessary to establish the durability of response and the absence of delayed adverse events. 
- Overcoming Immune Rejection: Off‑the‑shelf therapies must be engineered to escape host immune surveillance. This involves not only knocking out key immunogenic genes but also potentially engineering cells to express molecules such as HLA‑E to blunt NK cell–mediated clearance. 
- Standardizing Manufacturing Methods: The complexity of producing a consistent allogeneic product requires stringent quality control measures. Harmonization of gene editing processes, cell expansion protocols, and safety testing must meet the high standards demanded by regulatory agencies. 
- Balancing Efficacy with Toxicity: The metabolic activation, cytokine secretion kinetics, and potential overactivation must be finely tuned so that the antitumor efficacy does not come at the expense of life-threatening toxicities such as CRS and neurotoxicity. 
- Navigating Regulatory Hurdles: Given the novel nature of universal CAR‑T, regulatory guidelines are rapidly evolving. Engaging early with regulatory bodies such as the FDA to design preclinical and clinical studies that address their concerns is imperative for eventual market approval.

Researchers are actively exploring these challenges through innovative engineering solutions, adaptive clinical trial designs, and real-world evidence accumulation. As these challenges are addressed, the gap between promising experimental results and regulatory approval will ideally narrow, paving the way for universal CAR‑T to become a mainstream therapeutic option in oncology.

Conclusion

In summary, CAR‑T cell therapy has revolutionized cancer treatment by harnessing a patient’s own T cells to selectively target and eliminate malignant cells. The revolutionary aspect of CAR‑T therapy lies in its customizable structure—enabling potent antitumor activity through genetically engineered T cells that bypass conventional immune recognition pathways. Autologous CAR‑T therapies have already achieved remarkable success with several FDA approved products available for treating hematological malignancies.

Universal CAR‑T therapy, in contrast, represents a next-generation approach that promises several advantages over its autologous counterparts including reduced manufacturing time, lower cost, and consistent product quality by leveraging allogeneic cells from healthy donors. Innovations in gene editing technology, such as CRISPR/Cas9, have significantly advanced the development of these “off‑the‑shelf” products by enabling the elimination of T‑cell receptors and HLA molecules that are responsible for graft-versus-host reactions. Despite these technological progresses and the numerous ongoing trials, universal CAR‑T therapies have not yet secured FDA approval. To date, there are no FDA approved universal CAR‑T cell therapies available, and all currently authorized CAR‑T products are autologous in nature.

The FDA approval process for CAR‑T therapies demands robust evidence of safety, manufacturing consistency, and long-term efficacy. For universal CAR‑T products, additional challenges such as ensuring immune compatibility, mitigating the risk of GvHD, and standardizing complex manufacturing processes must be thoroughly addressed. While early-phase clinical trials show promising antitumor activity, the lack of long-term follow-up data and the considerable technical and regulatory hurdles currently preclude these products from gaining regulatory approval.

Looking ahead, ongoing research and clinical trials are expected to generate more comprehensive data on safety and efficacy, which—if successful—will likely pave the way for universal CAR‑T therapies to transition from an experimental stage to clinical reality. This progress will mark a significant breakthrough in cancer therapy by offering a readily available and potentially more cost‑effective treatment alternative that can be administered rapidly to a broader patient population. The collaboration between academia, industry, and clinical institutions, paired with innovative cell engineering strategies, is essential to overcome these challenges and drive universal CAR‑T therapy toward eventual FDA approval.

In conclusion, while universal CAR‑T cell therapy holds immense promise for the future of cancer immunotherapy, particularly with respect to improving access, reducing treatment time, and standardizing product quality, there are currently no FDA approved universal CAR‑T therapies on the market. Autologous CAR‑T therapies remain the only FDA approved products, underscoring the importance of continued research and clinical investigation to fully realize the potential of universal, off‑the‑shelf CAR‑T cell treatment strategies.

Curious to see how Eureka LS fits into your workflow? From reducing screening time to simplifying Markush drafting, our AI Agents are ready to deliver immediate value. Explore Eureka LS today and unlock powerful capabilities that help you innovate with confidence.